OR8B12

Across TCGA pan-cancer cohorts, OR8B12 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated OR8B12 data layer compared with 7 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher OR8B12 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR8B12 expression acts as an unfavorable survival marker.

HNSC, SCLC, and LUSC are the cancer types where OR8B12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.058	0.674	<.001	29	view →
SCLC	DFS	Median	All	0.268	0.644	.002	15	view →
LUSC	OS	Median	III,IV	0.112	0.664	.003	12	view →
LAML	DFS	Median	All	0.112	0.582	.010	6	view →
BLCA	DFS	Median	All	0.015	0.594	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

OR8B12–HNSC (OS)

Open the HNSC breakdown →